DENVER, CO, United States, via eTeligis Inc., 07/02/2014 - - CannLabs, Inc., (OTCQB: SDSPD) announced today its inclusion on the Benzinga 420 Marijuana Index, which tracks changes and growth in the industry's publicly traded stocks, as of June 30th, 2014.
"Our spot on the Index further validates our recent move to the public markets, and our place in the rapidly growing cannabis industry," said Genifer Murray CEO of CannLabs. "We hope this inclusion will contribute to our liquidity and create awareness among new investors."
The Benzinga 420 Marijuana Index, launched earlier this year, began with a value of 100 at year-end 2012, ended 2013 at 159, peaked at 1010 in March and is currently just above the recent 360 post-peak low. Each quarter, the index is rebalanced and updated to include names that qualify. The number of companies will increase from 27 as of 3/31 to 45 as of 6/30. Inclusion is based on a number of factors, such as trading volume, market cap and perception of being focused on cannabis. For 2013, there were only 8 stocks in the index. More information about the Index can be found at: http://www.benzinga.com/index/$BZMJ
ABOUT CANNLABS
CannLabs, Inc., is a solutions provider with intellectual property, proprietary cloud-based analytics and scientific methods to serve the cannabis industry. Through Carbon Bond Holdings Inc., CannLabs provides laboratories with the necessary business intelligence technology and other solutions required to serve the cannabis industry, and these include the first state-licensed laboratory in Denver, Colorado.
CannLabs enables growers, dispensaries and edible makers to implement best practices while furthering product advancements. In addition, the CannLabs website allows consumers to easily locate certified tested products to meet their specific needs.
CannLabs has been at the forefront of educating the public, in addition to state and local governments as more states legalize marijuana for various uses. The Company provides client education around safe cultivation, identifying contamination problems, consulting on legal cases and the reformulation of cannabis products, throughout the U.S. and Canada.
The Company plans to license their solutions to new labs and other cannabis companies in states and provinces as legislation and testing mandates for legalization are approved. This will allow the Company to further scale its data analytics and consulting business across a broader geographic area. In addition, the CannLabs team will focus on research and development which will further drive value for their customers and provide incremental revenue opportunity.
For more information visit www.cannlabs.com.
Safe Harbor Statement
All statements herein other than statements of historical facts are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Such statements are not guarantees of future performance and are subject to known and unknown risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements. Such factors include, but are not limited to, our ability to raise additional capital, our limited operating history and revenue, our ability to attract and retain qualified personnel, our ability to develop new services, market acceptance of our services, legislative, regulatory and competitive developments in our industry, general economic conditions, as well as other factors set forth in our filings with the SEC.
CONTACT:
Company
Robert Farrell
Vice President of Marketing
855-842-6936
Investor Relations
Matt Hayden
Chairman - MZ North America
949-259-4986
SOURCE: CannLabs, Inc.
Associated Documentation:
Link to submission on http://www.eteligis.com
SDSPD_7-2-2014_ALD_ETL.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment